|Table of Contents|
Catheter-guided renal sympathetic denervation in patients with therapy-refractory hypertension
Hypertension is the leading cause of cardiovascular disease worldwide, with a prevalence of 30–40% in the West and 20–35% in the Middle East. More than50% of patients have inadequate blood pressure control despite combined antihypertensive medication. Reasons for the failure to achieve recommended blood pressure values include lack of patient compliance and inefficiency of antihypertensive treatment (therapy-refractory hypertension).
Symplicity HTNI. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension. 2011; 57:911–17. http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.163014
Symplicity HTNI, Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9. http://dx.doi.org/10.1016/S0140-6736(10)62039-9